At the J.P. Morgan Healthcare Conference, GlaxoSmithKline (NYSE: GSK) CEO Andrew Witty made headlines when he signaled that he might be open to splitting the pharma giant in separate parts, a move some investors say would unlock more value.
{iframe}http://www.bizjournals.com/triangle/news/2016/01/15/how-a-gsk-spinoff-might-affect-the-triangle-if-it.html{/iframe}